Sun Pharma’s head of biologics marketing Maureen Shannon said, “We are so honored to partner with Art Garfunkel to share his ...

Sun Pharma will nab Checkpoint’s anti-PD-L1 antibody cosibelimab, known by its brand name Unloxcyt, and approved by the FDA in December to treat advanced cutaneous squamous cell carcinoma, a type of ...

Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer, said, “The fourth quarter of 2024 was transformational for Fortress, marked by two FDA approvals — Emrosi™ and ...

This transaction is also a successful milestone for Fortress as we expect to receive approximately $28 million at closing in addition to a 2.5% royalty on net sales of UNLOXCYT, and up to an ...

UNLOXCYT is a human immunoglobulin G1 monoclonal antibody that binds PD-L1 and blocks the interaction between PD-L1 and its T cell receptors, PD-1 and B7.1. This interaction releases the inhibitory ...